Temat: "Fibrosis" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: NXC736 Attenuates Radiation-Induced Lung Fibrosis via Regulating NLRP3/IL-1β Signaling Pathway.
Autorzy:: Kim SY; Department of Radiation Oncology, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
Park S; Department of Radiation Oncology, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
Cui R; Department of Radiation Oncology, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
Lee H; Department of Radiation Oncology, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
Choi H; Nextgen Bioscience, Bundang-gu, Seongnam-si 13487, Gyeonggi-do, Republic of Korea.
Farh ME; Department of Radiation Oncology, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
Jo HI; Department of Radiation Oncology, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
Lee JH; Department of Radiation Oncology, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
Song HJ; Department of Radiation Oncology, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
Lee YJ; Korea Institute of Radiological and Medical Science, Seoul 01812, Republic of Korea.
Lee YS; Graduate School of Pharmaceutical Sciences and College of Pharmacy, Ewha Womans University, Seoul 03760, Republic of Korea.
Lee BY; Nextgen Bioscience, Bundang-gu, Seongnam-si 13487, Gyeonggi-do, Republic of Korea.
Cho J; Department of Radiation Oncology, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2023 Nov 13; Vol. 24 (22). Date of Electronic Publication: 2023 Nov 13.
Typ publikacji:: Journal Article
MeSH Terms:: Pulmonary Fibrosis*/drug therapy
Pulmonary Fibrosis*/etiology
Pulmonary Fibrosis*/metabolism
Radiation Injuries*/metabolism
Mice ; Animals ; NLR Family, Pyrin Domain-Containing 3 Protein/metabolism ; Lung/pathology ; Fibrosis ; Inflammasomes/metabolism ; Signal Transduction ; Radiation Fibrosis Syndrome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Effects of modulator therapies on endocrine complications in adults with cystic fibrosis: a narrative review.
Autorzy:: Kumar S; Monash Centre for Health Research and Implementation, Monash University, Melbourne, VIC.; Adult Cystic Fibrosis Centre, Prince Charles Hospital, Brisbane, QLD.
Soldatos G; Monash Centre for Health Research and Implementation, Monash University, Melbourne, VIC.; Monash Health, Melbourne, VIC.
Teede HJ; Monash Centre for Health Research and Implementation, Monash University, Melbourne, VIC.; Monash Health, Melbourne, VIC.
Pallin M; Monash Health, Melbourne, VIC.; Pokaż więcej
Źródło:: The Medical journal of Australia [Med J Aust] 2023 Nov 20; Vol. 219 (10), pp. 496-502. Date of Electronic Publication: 2023 Oct 15.
Typ publikacji:: Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:: Cystic Fibrosis*/complications
Cystic Fibrosis*/drug therapy
Cystic Fibrosis*/genetics
Diabetes Mellitus, Type 2*/drug therapy
Pregnancy ; Female ; Adult ; Humans ; Cystic Fibrosis Transmembrane Conductance Regulator/genetics ; Cystic Fibrosis Transmembrane Conductance Regulator/therapeutic use ; Mutation ; Quality of Life

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 3.

Tytuł:: Update on Cystic Fibrosis in Pediatric Patients.
Autorzy:: Lusman SS; Division of Pediatric Gastroenterology, Hepatology and Nutrition, Columbia University Irving Medical Center, 622 West 168th Street, PH 17 East - 105L, New York, NY, 10032, USA. .; Pokaż więcej
Źródło:: Current gastroenterology reports [Curr Gastroenterol Rep] 2023 Nov; Vol. 25 (11), pp. 308-315. Date of Electronic Publication: 2023 Sep 01.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Cystic Fibrosis*/therapy
Cystic Fibrosis*/drug therapy
Gastrointestinal Diseases*/therapy
Humans ; Child ; Cystic Fibrosis Transmembrane Conductance Regulator/genetics ; Cystic Fibrosis Transmembrane Conductance Regulator/therapeutic use ; Quality of Life ; Biomarkers ; Mutation

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 4.

Tytuł:: Lung Inflammatory Genes in Cystic Fibrosis and Their Relevance to Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapies.
Autorzy:: Carbone A; Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy.
Vitullo P; Cystic Fibrosis Support Center, Ospedale 'G. Tatarella', 71042 Cerignola, Italy.
Di Gioia S; Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy.
Conese M; Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy.; Pokaż więcej
Źródło:: Genes [Genes (Basel)] 2023 Oct 20; Vol. 14 (10). Date of Electronic Publication: 2023 Oct 20.
Typ publikacji:: Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:: Cystic Fibrosis*/drug therapy
Cystic Fibrosis*/genetics
Pneumonia*
Humans ; Cystic Fibrosis Transmembrane Conductance Regulator/genetics ; Cystic Fibrosis Transmembrane Conductance Regulator/therapeutic use ; Inflammation/drug therapy ; Inflammation/genetics ; Lung

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 5.

Tytuł:: Epigenetic hallmarks in pulmonary fibrosis: New advances and perspectives.
Autorzy:: Zhang YS; Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, PR China.
Tu B; Department of Cardiothoracic Surgery, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, PR China.
Song K; Department of Cardiothoracic Surgery, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, PR China.
Lin LC; Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, PR China.
Liu ZY; Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, PR China.
Lu D; Department of Interventional Radiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, PR China. Electronic address: .
Chen Q; Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, PR China. Electronic address: .
Tao H; Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, PR China; Department of Cardiothoracic Surgery, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, PR China. Electronic address: .; Pokaż więcej
Źródło:: Cellular signalling [Cell Signal] 2023 Oct; Vol. 110, pp. 110842. Date of Electronic Publication: 2023 Aug 05.
Typ publikacji:: Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:: Pulmonary Fibrosis*/genetics
Pulmonary Fibrosis*/pathology
Idiopathic Pulmonary Fibrosis*/drug therapy
Humans ; Lung/pathology ; Epigenesis, Genetic ; Fibroblasts/pathology ; Fibrosis

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 6.

Tytuł:: Nutritional management of people living with cystic fibrosis throughout life and disease continuum: Changing times, new challenges.
Autorzy:: Mailhot G; Department of Nutrition, Faculty of Medicine, Montreal, QC, Canada.; CHU Sainte-Justine Research Center, Montreal, QC, Canada.
Denis MH; Cystic Fibrosis Clinic, CHU Sainte-Justine, Montreal, QC, Canada.
Beauchamp-Parent C; Department of Nutrition, Faculty of Medicine, Montreal, QC, Canada.
Jomphe V; Lung Transplant Program, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada.; Pokaż więcej
Źródło:: Journal of human nutrition and dietetics : the official journal of the British Dietetic Association [J Hum Nutr Diet] 2023 Oct; Vol. 36 (5), pp. 1675-1691. Date of Electronic Publication: 2023 Jul 28.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Cystic Fibrosis*/complications
Cystic Fibrosis*/genetics
Cystic Fibrosis*/therapy
Humans ; Cystic Fibrosis Transmembrane Conductance Regulator/genetics ; Cystic Fibrosis Transmembrane Conductance Regulator/metabolism ; Cystic Fibrosis Transmembrane Conductance Regulator/therapeutic use ; Prognosis ; Lung ; Precision Medicine

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 7.

Tytuł:: Non-peptidic immunoproteasome β5i-selective inhibitor as potential treatment for idiopathic pulmonary fibrosis: Virtual screening, hit evolution and lead identification.
Autorzy:: Li Y; NHC Key Laboratory of Biotechnology of Antibiotics, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China.
Nan G; Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.
Hou X; Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.
Yan Y; NHC Key Laboratory of Biotechnology of Antibiotics, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China.
Yang Y; Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.
Yang Y; Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.
Li K; NHC Key Laboratory of Biotechnology of Antibiotics, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China. Electronic address: .
Xiao Z; Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China. Electronic address: .; Pokaż więcej
Źródło:: European journal of medicinal chemistry [Eur J Med Chem] 2023 Dec 05; Vol. 261, pp. 115856. Date of Electronic Publication: 2023 Oct 06.
Typ publikacji:: Journal Article
MeSH Terms:: Idiopathic Pulmonary Fibrosis*/chemically induced
Idiopathic Pulmonary Fibrosis*/drug therapy
Mice ; Animals ; Bleomycin/pharmacology ; Fibrosis ; NF-kappa B ; Lung/pathology

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 8.

Tytuł:: Cystic fibrosis: Does it matter to avoid crushing Elexacaftor/Tezacaftor/Ivacaftor (ETI) tablets?
Autorzy:: Lebecque P; Cystic Fibrosis Reference Center of Liège, CHC MontLegia, Liège, Belgium.
Thimmesch M; Cystic Fibrosis Reference Center of Liège, CHC MontLegia, Liège, Belgium.
Meurrens J; Cystic Fibrosis Reference Center of Liège, CHC MontLegia, Liège, Belgium.
Jeanmart P; Clinical Chemistry Department, CHC MontLegia, Liège, Belgium.; Pokaż więcej
Źródło:: Pediatric pulmonology [Pediatr Pulmonol] 2023 Dec; Vol. 58 (12), pp. 3603-3604. Date of Electronic Publication: 2023 Sep 13.
Typ publikacji:: Journal Article
MeSH Terms:: Cystic Fibrosis*/drug therapy
Cystic Fibrosis*/genetics
Humans ; Aminophenols/therapeutic use ; Benzodioxoles/therapeutic use ; Pyrazoles ; Cystic Fibrosis Transmembrane Conductance Regulator/genetics ; Mutation ; Chloride Channel Agonists/therapeutic use

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 9.

Tytuł:: Real-life experience with a generic formulation of lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for the Phe508del CFTR mutation.
Autorzy:: Teper A; Division of Respiratory, Hospital de Niños Ricardo Gutiérrez, Ciudad de Buenos Aires, Argentina.
Lubovich S; Division of Respiratory, Hospital de Niños Ricardo Gutiérrez, Ciudad de Buenos Aires, Argentina.
Rodríguez V; Division of Respiratory, Hospital de Niños Ricardo Gutiérrez, Ciudad de Buenos Aires, Argentina.
Zaragoza S; Division of Respiratory, Hospital de Niños Ricardo Gutiérrez, Ciudad de Buenos Aires, Argentina.
Rodríguez E; Division of Respiratory, Hospital de Niños Ricardo Gutiérrez, Ciudad de Buenos Aires, Argentina.
Bournissen FG; Department of Paediatrics, Schulich School of Medicine and Dentistry Western University, London, Ontario, Canada.; Pokaż więcej
Źródło:: Pediatric pulmonology [Pediatr Pulmonol] 2023 Dec; Vol. 58 (12), pp. 3560-3565. Date of Electronic Publication: 2023 Sep 15.
Typ publikacji:: Journal Article
MeSH Terms:: Cystic Fibrosis*/drug therapy
Cystic Fibrosis*/genetics
Humans ; Male ; Child ; Adolescent ; Female ; Cystic Fibrosis Transmembrane Conductance Regulator/therapeutic use ; Drug Combinations ; Aminophenols ; Aminopyridines ; Benzodioxoles/adverse effects ; Mutation

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 10.

Tytuł:: Disruption of extracellular redox balance drives persistent lung fibrosis and impairs fibrosis resolution.
Autorzy:: Cui Y; Department of Immunology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, People's Republic of China. Electronic address: .
Yang Z; Interventional Radiology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, People's Republic of China.
Lv Z; Department of Immunology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, People's Republic of China.
Lei J; Medical Imaging Laboratory, Research Core Facilities, Capital Medical University, Beijing 100069, People's Republic of China.; Pokaż więcej
Źródło:: Biochimica et biophysica acta. Molecular basis of disease [Biochim Biophys Acta Mol Basis Dis] 2023 Dec; Vol. 1869 (8), pp. 166842. Date of Electronic Publication: 2023 Aug 07.
Typ publikacji:: Journal Article
MeSH Terms:: Pulmonary Fibrosis*/chemically induced
Pulmonary Fibrosis*/genetics
Pulmonary Fibrosis*/metabolism
Mice ; Animals ; Reactive Oxygen Species/metabolism ; Fibrosis ; Bleomycin ; Oxidation-Reduction

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 11.

Tytuł:: Use of CFTR modulators in special populations, part 3: Solid organ transplant.
Autorzy:: Kadouh NK; Department of Pharmacy Services, Michigan Medicine, Ann Arbor, Michigan, USA.; Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.
Elijah J; Department of Pharmacy Services, Michigan Medicine, Ann Arbor, Michigan, USA.; Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.
Fitzgerald LJ; Department of Pharmacy Services, Michigan Medicine, Ann Arbor, Michigan, USA.; Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.; Sanofi Medical Affairs, Bridgewater, New Jersey, USA.
Phan H; Department of Pharmacy Services, Michigan Medicine, Ann Arbor, Michigan, USA.; Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.; Susan B. Meister Child Health Evaluation and Research (CHEAR) Center, University of Michigan, Ann Arbor, Michigan, USA.; Pokaż więcej
Źródło:: Pediatric pulmonology [Pediatr Pulmonol] 2023 Dec; Vol. 58 (12), pp. 3393-3402. Date of Electronic Publication: 2023 Apr 17.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Organ Transplantation*
Cystic Fibrosis*/drug therapy
Cystic Fibrosis*/surgery
Humans ; Cystic Fibrosis Transmembrane Conductance Regulator/genetics ; Cohort Studies ; Tacrolimus ; Aminophenols/therapeutic use ; Mutation ; Benzodioxoles

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 12.

Tytuł:: Improvement in cystic fibrosis newborn screening program outcomes with genetic counseling via telemedicine.
Autorzy:: Stalker HJ; Hayward Telegenetics Center, Division of Pediatric Genetics and Metabolism, University of Florida, Gainesville, Florida, USA.
Jonasson AR; Hayward Telegenetics Center, Division of Pediatric Genetics and Metabolism, University of Florida, Gainesville, Florida, USA.
Hopfer SM; Pathology and Laboratory Medicine, University of Connecticut School of Medicine, Farmington, Connecticut, USA.
Collins MS; Central Connecticut Cystic Fibrosis Center/Connecticut Childrens' Medical Center, Division of Pediatric Pulmonary and Sleep Medicine, University of Connecticut School of Medicine, Farmington, Connecticut, USA.; Pokaż więcej
Źródło:: Pediatric pulmonology [Pediatr Pulmonol] 2023 Dec; Vol. 58 (12), pp. 3478-3486. Date of Electronic Publication: 2023 Sep 15.
Typ publikacji:: Journal Article
MeSH Terms:: Genetic Counseling*/methods
Cystic Fibrosis*/diagnosis
Cystic Fibrosis*/genetics
Cystic Fibrosis*/psychology
Infant ; Infant, Newborn ; Child ; Humans ; Neonatal Screening/methods ; Genetic Carrier Screening/methods ; Cystic Fibrosis Transmembrane Conductance Regulator/genetics ; Genetic Testing

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 13.

Tytuł:: Pulmonary fibrosis: from pathogenesis to clinical decision-making.
Autorzy:: Koudstaal T; Department of Pulmonary Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands. Electronic address: .
Funke-Chambour M; Department of Pulmonary Medicine, Inselspital, University Hospital Bern, Bern, Switzerland.
Kreuter M; Mainz Center for Pulmonary Medicine, Departments of Pneumology, Mainz University Medical Center and of Pulmonary, Critical Care & Sleep Medicine, Marienhaus Clinic Mainz, Mainz, Germany.
Molyneaux PL; Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Wijsenbeek MS; Department of Pulmonary Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.; Pokaż więcej
Źródło:: Trends in molecular medicine [Trends Mol Med] 2023 Dec; Vol. 29 (12), pp. 1076-1087. Date of Electronic Publication: 2023 Sep 14.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Pulmonary Fibrosis*/diagnosis
Pulmonary Fibrosis*/etiology
Pulmonary Fibrosis*/therapy
Lung Diseases, Interstitial*/diagnosis
Lung Diseases, Interstitial*/etiology
Lung Diseases, Interstitial*/therapy
Humans ; Quality of Life ; Lung ; Fibrosis ; Clinical Decision-Making

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 14.

Tytuł:: In vitro co-culture studies and the crucial role of fibroblast-immune cell crosstalk in IPF pathogenesis.
Autorzy:: Thiam F; Department of Biology, University of British Columbia, 3187 University Way, ASC366, Kelowna, BC, V1V1V7, Canada.
Phogat S; Department of Biology, University of British Columbia, 3187 University Way, ASC366, Kelowna, BC, V1V1V7, Canada.
Abokor FA; Department of Biology, University of British Columbia, 3187 University Way, ASC366, Kelowna, BC, V1V1V7, Canada.
Osei ET; Department of Biology, University of British Columbia, 3187 University Way, ASC366, Kelowna, BC, V1V1V7, Canada. .; Centre for Heart Lung Innovation, St. Paul's Hospital, Vancouver, BC, Canada. .; Pokaż więcej
Źródło:: Respiratory research [Respir Res] 2023 Nov 27; Vol. 24 (1), pp. 298. Date of Electronic Publication: 2023 Nov 27.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Idiopathic Pulmonary Fibrosis*/metabolism
Humans ; Coculture Techniques ; Lung/metabolism ; Fibroblasts/metabolism ; Fibrosis

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: Functional Pdgfra fibroblast heterogeneity in normal and fibrotic mouse lung.
Autorzy:: Trempus CS; Immunity, Inflammation, and Disease Laboratory.
Papas BN; Biostatistics & Computational Biology Branch.
Sifre MI; Signal Transduction Laboratory, and.
Bortner CD; Signal Transduction Laboratory, and.
Scappini E; Signal Transduction Laboratory, and.
Tucker CJ; Signal Transduction Laboratory, and.
Xu X; Epigenetics & Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, North Carolina, USA.
Johnson KL; Epigenetics & Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, North Carolina, USA.
Deterding LJ; Epigenetics & Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, North Carolina, USA.
Williams JG; Epigenetics & Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, North Carolina, USA.
Johnson DJ; Biostatistics & Computational Biology Branch.
Li JL; Biostatistics & Computational Biology Branch.
Sutton D; Comparative & Molecular Pathogenesis Branch, National Institute of Environmental Health Sciences, Division of Translational Toxicology, Research Triangle Park, North Carolina, USA.
Ganta C; Comparative & Molecular Pathogenesis Branch, National Institute of Environmental Health Sciences, Division of Translational Toxicology, Research Triangle Park, North Carolina, USA.; Inotiv, Research Triangle Park, North Carolina, USA.
Mahapatra D; Inotiv, Research Triangle Park, North Carolina, USA.
Arif M; Section on Fibrotic Disorders, and.; Laboratory of Cardiovascular Physiology and Tissue Injury, National Institute on Alcohol Abuse and Alcoholism, NIH, Rockville, Maryland, USA.
Basu A; Section on Fibrotic Disorders, and.
Pommerolle L; Section on Fibrotic Disorders, and.
Cinar R; Section on Fibrotic Disorders, and.
Perl AK; Division of Pulmonary Biology, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Garantziotis S; Immunity, Inflammation, and Disease Laboratory.; Pokaż więcej
Źródło:: JCI insight [JCI Insight] 2023 Nov 22; Vol. 8 (22). Date of Electronic Publication: 2023 Nov 22.
Typ publikacji:: Journal Article
MeSH Terms:: Lung Injury*/pathology
Idiopathic Pulmonary Fibrosis*/chemically induced
Idiopathic Pulmonary Fibrosis*/genetics
Idiopathic Pulmonary Fibrosis*/metabolism
Mice ; Animals ; Fibrosis ; Lung/pathology ; Fibroblasts/metabolism ; Receptor Protein-Tyrosine Kinases/metabolism

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 16.

Tytuł:: A Novel Co-Culture Model Reveals Enhanced CFTR Rescue in Primary Cystic Fibrosis Airway Epithelial Cultures with Persistent Pseudomonas aeruginosa Infection.
Autorzy:: Cholon DM; Marsico Lung Institute and Cystic Fibrosis Research Center, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.
Greenwald MA; Marsico Lung Institute and Cystic Fibrosis Research Center, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.; Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC 27599, USA.
Higgs MG; Marsico Lung Institute and Cystic Fibrosis Research Center, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.; Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC 27599, USA.
Quinney NL; Marsico Lung Institute and Cystic Fibrosis Research Center, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.
Boyles SE; Marsico Lung Institute and Cystic Fibrosis Research Center, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.
Meinig SL; Marsico Lung Institute and Cystic Fibrosis Research Center, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.; Pharmaceutical Product Development (PPD), Thermo Fisher Scientific, Morrisville, NC 27560, USA.
Minges JT; Marsico Lung Institute and Cystic Fibrosis Research Center, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.
Chaubal A; Marsico Lung Institute and Cystic Fibrosis Research Center, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.
Tarran R; Marsico Lung Institute and Cystic Fibrosis Research Center, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.; Division of Genetic, Department of Internal Medicine, Environmental and Inhalational Disease, University of Kansas Medical Center, Kansas City, KS 66160, USA.
Ribeiro CMP; Marsico Lung Institute and Cystic Fibrosis Research Center, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.; Division of Pulmonary Diseases, Department of Medicine, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.; Department of Cell Biology and Physiology, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.
Wolfgang MC; Marsico Lung Institute and Cystic Fibrosis Research Center, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.; Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC 27599, USA.
Gentzsch M; Marsico Lung Institute and Cystic Fibrosis Research Center, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.; Department of Cell Biology and Physiology, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.; Division of Pediatric Pulmonology, Department of Pediatrics, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.; Pokaż więcej
Źródło:: Cells [Cells] 2023 Nov 13; Vol. 12 (22). Date of Electronic Publication: 2023 Nov 13.
Typ publikacji:: Journal Article
MeSH Terms:: Cystic Fibrosis*/metabolism
Pseudomonas Infections*/drug therapy
Pseudomonas Infections*/microbiology
Humans ; Cystic Fibrosis Transmembrane Conductance Regulator/genetics ; Cystic Fibrosis Transmembrane Conductance Regulator/metabolism ; Coculture Techniques ; Lung/metabolism

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 17.

Tytuł:: The impact of SARS-CoV-2 infection in patients with cystic fibrosis undergoing CFTR channel modulators treatment: a literature review.
Autorzy:: Vitiello A; Directorate General for Health Prevention, Ministry of Health, Rome, Italy.
Sabbatucci M; Directorate General for Health Prevention, Ministry of Health, Rome, Italy.; Department Infectious Diseases, National Institute of Health, Rome, Italy.
Silenzi A; Directorate General for Health Prevention, Ministry of Health, Rome, Italy.
Capuano A; Section of Pharmacology 'L. Donatelli', Department of Experimental Medicine, Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, University of Campania 'Luigi Vanvitelli', Naples, Italy.
Rossi F; Section of Pharmacology 'L. Donatelli', Department of Experimental Medicine, Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, University of Campania 'Luigi Vanvitelli', Naples, Italy.
Zovi A; Directorate General for Hygiene, Food Safety and Nutrition, Ministry of Health, Rome, Italy. .
Blasi F; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy. .; Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. .
Rezza G; Directorate General for Health Prevention, Ministry of Health, Rome, Italy.; Pokaż więcej
Źródło:: Respiratory research [Respir Res] 2023 Nov 13; Vol. 24 (1), pp. 278. Date of Electronic Publication: 2023 Nov 13.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Cystic Fibrosis*/drug therapy
Cystic Fibrosis*/metabolism
COVID-19*
Humans ; Cystic Fibrosis Transmembrane Conductance Regulator/genetics ; RNA, Viral ; SARS-CoV-2

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: A selective CB2R agonist (JWH133) protects against pulmonary fibrosis through inhibiting FAK/ERK/S100A4 signaling pathways.
Autorzy:: Wu X; Department of Critical Care Medicine, The Second People's Hospital of Guiyang, Guiyang, 550023, People's Republic of China.; Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Guizhou Medical University, Guiyang, 550004, People's Republic of China.
Chen L; Guiyang Public Health Clinical Center, Guiyang, 550004, People's Republic of China.; Guizhou Medical University, Guiyang, 550004, People's Republic of China.
Cheng Y; Department of Respiratory and Critical Care Medicine, The First People's Hospital of Guiyang, Guiyang, 550004, People's Republic of China. .; Guizhou Medical University, Guiyang, 550004, People's Republic of China. .
Zhang Y; Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Guizhou Medical University, Guiyang, 550004, People's Republic of China.
Yang W; Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Guizhou Medical University, Guiyang, 550004, People's Republic of China. .
Pan L; Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Guizhou Medical University, Guiyang, 550004, People's Republic of China.
Fu C; Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Guizhou Medical University, Guiyang, 550004, People's Republic of China.
Zhu H; Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Guizhou Medical University, Guiyang, 550004, People's Republic of China.
Zhang M; Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Guizhou Medical University, Guiyang, 550004, People's Republic of China.; Pokaż więcej
Źródło:: BMC pulmonary medicine [BMC Pulm Med] 2023 Nov 13; Vol. 23 (1), pp. 440. Date of Electronic Publication: 2023 Nov 13.
Typ publikacji:: Journal Article
MeSH Terms:: Cannabinoid Receptor Agonists*/pharmacology
Pulmonary Fibrosis*/chemically induced
Pulmonary Fibrosis*/drug therapy
Signal Transduction*/drug effects
Animals ; Mice ; Bleomycin ; Fibrosis ; Focal Adhesion Protein-Tyrosine Kinases/antagonists & inhibitors ; Lung/pathology

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 19.

Tytuł:: Establishment and application of the BRP prognosis model for idiopathic pulmonary fibrosis.
Autorzy:: Cheng X; Department of Pulmonary and Critical Care Medicine, The Third Xiangya Hospital of Central South University, Tongzipo Road 138, Yuelu District, Changsha, 410000, Hunan, China.; Hunan Key Laboratory of Organ Fibrosis, Tongzipo Road 138, Yuelu District, Changsha, 410000, China.
Feng Z; Departments of Radiology, The Third Xiangya Hospital of Central South University, Tongzipo Road 138, Yuelu District, Changsha, 410000, Hunan, China.
Pan B; Departments of Orthopedics, The Third Xiangya Hospital of Central South University, Tongzipo Road 138, Yuelu District, Changsha, 410000, Hunan, China.
Liu Q; Hunan Key Laboratory of Organ Fibrosis, Tongzipo Road 138, Yuelu District, Changsha, 410000, China.
Han Y; Department of Pulmonary and Critical Care Medicine, The Third Xiangya Hospital of Central South University, Tongzipo Road 138, Yuelu District, Changsha, 410000, Hunan, China.; Hunan Key Laboratory of Organ Fibrosis, Tongzipo Road 138, Yuelu District, Changsha, 410000, China.
Zou L; Department of Pulmonary and Critical Care Medicine, The Third Xiangya Hospital of Central South University, Tongzipo Road 138, Yuelu District, Changsha, 410000, Hunan, China.; Hunan Key Laboratory of Organ Fibrosis, Tongzipo Road 138, Yuelu District, Changsha, 410000, China.
Rong P; Departments of Radiology, The Third Xiangya Hospital of Central South University, Tongzipo Road 138, Yuelu District, Changsha, 410000, Hunan, China. .
Meng J; Department of Pulmonary and Critical Care Medicine, The Third Xiangya Hospital of Central South University, Tongzipo Road 138, Yuelu District, Changsha, 410000, Hunan, China. .; Hunan Key Laboratory of Organ Fibrosis, Tongzipo Road 138, Yuelu District, Changsha, 410000, China. .; Pokaż więcej
Źródło:: Journal of translational medicine [J Transl Med] 2023 Nov 11; Vol. 21 (1), pp. 805. Date of Electronic Publication: 2023 Nov 11.
Typ publikacji:: Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Idiopathic Pulmonary Fibrosis*/diagnostic imaging
Idiopathic Pulmonary Fibrosis*/pathology
Humans ; Lung/pathology ; Prognosis ; Vital Capacity ; Biomarkers ; Fibrosis ; Retrospective Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 20.

Tytuł:: Lung SORT LNPs enable precise homology-directed repair mediated CRISPR/Cas genome correction in cystic fibrosis models.
Autorzy:: Wei T; Department of Biomedical Engineering, Program in Genetic Drug Engineering, The University of Texas Southwestern Medical Center, Dallas, TX, USA.; Department of Biochemistry, The University of Texas Southwestern Medical Center, Dallas, TX, USA.; Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
Sun Y; Department of Biomedical Engineering, Program in Genetic Drug Engineering, The University of Texas Southwestern Medical Center, Dallas, TX, USA.; Department of Biochemistry, The University of Texas Southwestern Medical Center, Dallas, TX, USA.; Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
Cheng Q; Department of Biomedical Engineering, Program in Genetic Drug Engineering, The University of Texas Southwestern Medical Center, Dallas, TX, USA.; Department of Biochemistry, The University of Texas Southwestern Medical Center, Dallas, TX, USA.; Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
Chatterjee S; Department of Biomedical Engineering, Program in Genetic Drug Engineering, The University of Texas Southwestern Medical Center, Dallas, TX, USA.; Department of Biochemistry, The University of Texas Southwestern Medical Center, Dallas, TX, USA.; Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
Traylor Z; Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA.; Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Johnson LT; Department of Biomedical Engineering, Program in Genetic Drug Engineering, The University of Texas Southwestern Medical Center, Dallas, TX, USA.; Department of Biochemistry, The University of Texas Southwestern Medical Center, Dallas, TX, USA.; Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
Coquelin ML; ReCode Therapeutics, Menlo Park, CA, USA.
Wang J; ReCode Therapeutics, Menlo Park, CA, USA.
Torres MJ; ReCode Therapeutics, Menlo Park, CA, USA.
Lian X; Department of Biomedical Engineering, Program in Genetic Drug Engineering, The University of Texas Southwestern Medical Center, Dallas, TX, USA.; Department of Biochemistry, The University of Texas Southwestern Medical Center, Dallas, TX, USA.; Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
Wang X; Department of Biomedical Engineering, Program in Genetic Drug Engineering, The University of Texas Southwestern Medical Center, Dallas, TX, USA.; Department of Biochemistry, The University of Texas Southwestern Medical Center, Dallas, TX, USA.; Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
Xiao Y; Department of Biomedical Engineering, Program in Genetic Drug Engineering, The University of Texas Southwestern Medical Center, Dallas, TX, USA.; Department of Biochemistry, The University of Texas Southwestern Medical Center, Dallas, TX, USA.; Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
Hodges CA; Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA.; Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Siegwart DJ; Department of Biomedical Engineering, Program in Genetic Drug Engineering, The University of Texas Southwestern Medical Center, Dallas, TX, USA. .; Department of Biochemistry, The University of Texas Southwestern Medical Center, Dallas, TX, USA. .; Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, TX, USA. .; Pokaż więcej
Źródło:: Nature communications [Nat Commun] 2023 Nov 11; Vol. 14 (1), pp. 7322. Date of Electronic Publication: 2023 Nov 11.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:: Cystic Fibrosis*/therapy
Cystic Fibrosis*/drug therapy
Humans ; Mice ; Animals ; Cystic Fibrosis Transmembrane Conductance Regulator/genetics ; Cystic Fibrosis Transmembrane Conductance Regulator/metabolism ; CRISPR-Cas Systems/genetics ; RNA, Guide, CRISPR-Cas Systems ; Lung/metabolism ; RNA, Messenger/genetics ; RNA, Messenger/therapeutic use

Czasopismo naukowe

na półce

Szczegóły

Informacja

Wyszukujesz frazę ""Fibrosis"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język